Notebook

OLD NEWS REBORN TRANS-ATLANTIC MEDITATION AIDS HONORS FROM THE FRYING PAN TO THE PHARMACY CHEMIST HONORED BRAIN-PROTECTING DRUGS OLD NEWS REBORN The wild spike in the stock price earlier this month of Rockville, Md.-based biotechnology company EntreMed Inc. was sparked by a few remarks over dinner, says the company's chairman, John Holaday. The comments came from Nobel laureate James Watson, director of the Cold Spring Harbor Laboratory on Long Island, N.Y. He was praising the work of M. Judah

The Scientist Staff

May 24, 1998 | 7 min read

OLD NEWS REBORN

TRANS-ATLANTIC MEDITATION

AIDS HONORS

FROM THE FRYING PAN TO THE PHARMACY

CHEMIST HONORED

BRAIN-PROTECTING DRUGS OLD NEWS REBORN The wild spike in the stock price earlier this month of Rockville, Md.-based biotechnology company EntreMed Inc. was sparked by a few remarks over dinner, says the company's chairman, John Holaday. The comments came from Nobel laureate James Watson, director of the Cold Spring Harbor Laboratory on Long Island, N.Y. He was praising the work of M. Judah Folkman and colleagues at Children's Hospital in Boston, whose research has shown that protein inhibitors of angiogenesis, or blood vessel growth, cause a variety of tumors in mice to regress (H. Black, The Scientist, 12[9]:10, April 27, 1998). A New York Times reporter heard Watson's words and quoted him in a subsequent article as saying, "Judah is going to cure cancer in two years." EntreMed, which is...

Interested in reading more?

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!

Already a member?

Interested in reading more?

Become a Member of